ALNY Stock Analysis: Buy, Sell, or Hold?
ALNY - Alnylam Pharmaceuticals, Inc.
$219.00
-1.33 (-0.60%)
▼
5d:
-24.07%
30d:
-30.04%
90d:
-26.49%
HOLD
MODERATE Confidence
Analysis Updated: Aug 4, 2026 12:00 AM ET
Earnings: Jul 30, 2026
0d
Get Alerted When ALNY Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ALNY shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: ALNY shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$619.52
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$384.67
43.1% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ALNY is currently trading at $219.00, which is considered oversold relative to its 30-day fair value range of $246.61 to $310.69. From a valuation perspective, the stock is trading at a discount (Forward PE: 17.3) compared to its historical average (25.7). Remarkably, the market is currently pricing in an annual earnings decline of 12.3% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, ALNY is in a downtrend. Immediate support is located at $197.81, while resistance sits at $290.60.
Market Sentiment: ALNY has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $386.29 (+75.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ALNY is in a downtrend. Immediate support is located at $197.81, while resistance sits at $290.60.
Market Sentiment: ALNY has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $386.29 (+75.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$246.61 -
$310.69
Company Quality Score
42/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 75.3% below Wall St target ($386.29)
- CAUTION: 5-day price weakness (-24.1%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$246.61 -
$310.69
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$197.81
Resistance Level
$290.60
Current Trend
Downtrend
Technical data as of
Aug 4, 2026
Fundamental Context
Forward P/E (Next Year Est.)
17.31
Wall Street Target
$386.29
(+75.3%)
Revenue Growth (YoY)
66.9%
Profit Margin
16.1%
Valuation Discount vs History
-12.3% cheaper
PE vs Historical
17.3 vs 25.7
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-12.3%
(market-implied from PE analysis)
1-Year Target
$198.30
(-10%)
2-Year Target
$178.47
(-19%)
3-Year Target
$160.62
(-27%)
3-Yr Target (if PE normalizes)
(PE: 17→26)
$238.41
(+8%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.7, Growth: 42.2%)
$758.84
(+244%)
Base:
(SPY PE: 17.3, Growth: 42.2%)
$633.80
(+188%)
Bear:
(PE: 14.7, Growth: 42.2%)
$538.73
(+145%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (36x PE), but valuation improves significantly next year (17x PE) as earnings recover.
Trailing PE: 35.87 | Current EPS (TTM): $5.73
Bull Case
$452.14
(+105%)
Analyst growth 100.0%, PE expands to 39.5
Base Case
$411.04
(+87%)
Market implied 100.0%, PE stable at 35.9
Bear Case
$139.75
(-37%)
Severe decline -20.0%, PE contracts to 30.5
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 17.3 to 25.7
Stabilization Target:
$327.04
(+48.4%)
PE Expansion Potential:
+48.4%
Share & Embed Analysis
Last updated: August 04, 2026 4:30 PM ET
Data refreshes hourly during market hours. Next update: 5:30 PM
Data refreshes hourly during market hours. Next update: 5:30 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ALNY showing a specific setup today?
Insider Activity (6 Months)
0
Buys
15
Sells
Net
INSIDERS SELLING
Recent Transactions
Melissa Mclaughlin
SELL
2286 shares
2026-04-06
Melissa Mclaughlin
SELL
1624 shares
2026-04-02
Kevin Joseph Fitzgerald
SELL
1652 shares
2026-03-03
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$87 | 55 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$196 | 46 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$108 | 58 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$309 | 55 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$86 | 47 HOLD |
